GAMIDA CELL LTD's ticker is GMDA and the CUSIP is M47364100. A total of 72 filers reported holding GAMIDA CELL LTD in Q2 2021. The put-call ratio across all filers is 0.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $247,546 | +1178690.5% | 128,262 | +672.6% | 0.00% | – |
| Q4 2022 | $21 | -100.0% | 16,602 | -88.6% | 0.00% | – |
| Q3 2021 | $573,000 | +2.3% | 146,235 | +67.2% | 0.00% | – |
| Q2 2021 | $560,000 | -67.6% | 87,436 | -59.0% | 0.00% | -100.0% |
| Q1 2021 | $1,726,000 | -14.3% | 213,379 | -11.1% | 0.00% | 0.0% |
| Q4 2020 | $2,015,000 | +145.1% | 240,119 | +21.2% | 0.00% | 0.0% |
| Q3 2020 | $822,000 | -34.0% | 198,186 | -27.3% | 0.00% | -50.0% |
| Q2 2020 | $1,245,000 | +1331.0% | 272,459 | +848.3% | 0.00% | – |
| Q1 2020 | $87,000 | -42.0% | 28,732 | -17.7% | 0.00% | – |
| Q4 2019 | $150,000 | -49.8% | 34,897 | -49.5% | 0.00% | – |
| Q3 2019 | $299,000 | -48.8% | 69,077 | -39.9% | 0.00% | -100.0% |
| Q2 2019 | $584,000 | +167.9% | 115,010 | +505.4% | 0.00% | – |
| Q1 2019 | $218,000 | +3.8% | 18,996 | -9.9% | 0.00% | – |
| Q4 2018 | $210,000 | – | 21,082 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 2,858,558 | $18,323,000 | 2.20% |
| Stonepine Capital Management, LLC | 443,507 | $2,843,000 | 1.49% |
| Healthcare Value Capital, LLC | 75,000 | $481,000 | 0.96% |
| Laird Norton Wetherby Trust Company, LLC | 529,103 | $3,391,000 | 0.35% |
| Rock Springs Capital Management LP | 2,107,000 | $13,506,000 | 0.27% |
| FIRST MIDWEST BANK TRUST DIVISION | 276,724 | $1,774,000 | 0.24% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 107,000 | $682,000 | 0.18% |
| Platform Technology Partners | 45,375 | $291,000 | 0.12% |
| PREMIER ASSET MANAGEMENT LLC | 110,660 | $709,000 | 0.10% |
| Virtus ETF Advisers LLC | 34,842 | $223,000 | 0.09% |